Search for a rare disease
Other search option(s)
Methimazole embryofetopathy
Disease definition
A teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.
ORPHA:1923
Classification level: Disorder- Synonym(s):
- MMI/CMZ embryofetopathy
- MMI/CMZ embryopathy
- Methimazole/carbimazole embryofetopathy
- Methimazole/carbimazole embryopathy
- Prevalence: <1 / 1 000 000
- Inheritance: Not applicable
- Age of onset: Neonatal, Antenatal
- ICD-10: Q86.8
- OMIM: -
- UMLS: -
- MeSH: -
- GARD: 3573
- MedDRA: -
Additional information
Further information on this disease
Patient-centred resources for this disease
Research activities on this disease
Specialised Social Services
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.